| Therapeutic targeting of the NRF2 and KEAP1 partnership in chronic diseases A Cuadrado, AI Rojo, G Wells, JD Hayes, SP Cousin, WL Rumsey, ... Nature reviews Drug discovery 18 (4), 295-317, 2019 | 1152 | 2019 |
| Antitumor benzothiazoles. 26. 2-(3, 4-Dimethoxyphenyl)-5-fluorobenzothiazole (GW 610, NSC 721648), a simple fluorinated 2-arylbenzothiazole, shows potent and selective … CG Mortimer, G Wells, JP Crochard, EL Stone, TD Bradshaw, ... Journal of Medicinal Chemistry 49 (1), 179-185, 2006 | 597 | 2006 |
| Synthesis and biological properties of benzothiazole, benzoxazole, and chromen-4-one analogues of the potent antitumor agent 2-(3, 4-dimethoxyphenyl)-5-fluorobenzothiazole (PMX … S Aiello, G Wells, EL Stone, H Kadri, R Bazzi, DR Bell, MFG Stevens, ... Journal of Medicinal Chemistry 51 (16), 5135-5139, 2008 | 407 | 2008 |
| The pharmacological regulation of cellular mitophagy ND Georgakopoulos, G Wells, M Campanella Nature chemical biology 13 (2), 136-146, 2017 | 302 | 2017 |
| Design, Synthesis, and Biophysical and Biological Evaluation of a Series of Pyrrolobenzodiazepine−Poly(N-methylpyrrole) Conjugates G Wells, CRH Martin, PW Howard, ZA Sands, CA Laughton, A Tiberghien, ... Journal of medicinal chemistry 49 (18), 5442-5461, 2006 | 179 | 2006 |
| Peptide inhibitors of the Keap1–Nrf2 protein–protein interaction R Hancock, HC Bertrand, T Tsujita, S Naz, A El-Bakry, J Laoruchupong, ... Free Radical Biology and Medicine 52 (2), 444-451, 2012 | 171 | 2012 |
| PMI: a ΔΨm independent pharmacological regulator of mitophagy DA East, F Fagiani, J Crosby, ND Georgakopoulos, H Bertrand, M Schaap, ... Chemistry & biology 21 (11), 1585-1596, 2014 | 164 | 2014 |
| Antitumour properties of fluorinated benzothiazole-substituted hydroxycyclohexa-2, 5-dienones (‘quinols’) CJ Lion, CS Matthews, G Wells, TD Bradshaw, MFG Stevens, ... Bioorganic & medicinal chemistry letters 16 (19), 5005-5008, 2006 | 149 | 2006 |
| Antitumour benzothiazoles. Part 10: the synthesis and antitumour activity of benzothiazole substituted quinol derivatives G Wells, TD Bradshaw, P Diana, A Seaton, DF Shi, AD Westwell, ... Bioorganic & medicinal chemistry letters 10 (5), 513-515, 2000 | 148 | 2000 |
| Direct Keap1-Nrf2 disruption as a potential therapeutic target for Alzheimer’s disease F Kerr, O Sofola-Adesakin, DK Ivanov, J Gatliff, B Gomez Perez-Nievas, ... PLoS genetics 13 (3), e1006593, 2017 | 143 | 2017 |
| 4-Substituted 4-hydroxycyclohexa-2, 5-dien-1-ones with selective activities against colon and renal cancer cell lines G Wells, JM Berry, TD Bradshaw, AM Burger, A Seaton, B Wang, ... Journal of medicinal chemistry 46 (4), 532-541, 2003 | 141 | 2003 |
| Molecular basis for the disruption of Keap1–Nrf2 interaction via Hinge & Latch mechanism Y Horie, T Suzuki, J Inoue, T Iso, G Wells, TW Moore, T Mizushima, ... Communications Biology 4 (1), 576, 2021 | 131 | 2021 |
| Design, synthesis, and evaluation of triazole derivatives that induce Nrf2 dependent gene products and inhibit the Keap1–Nrf2 protein–protein interaction HC Bertrand, M Schaap, L Baird, ND Georgakopoulos, A Fowkes, ... Journal of medicinal chemistry 58 (18), 7186-7194, 2015 | 128 | 2015 |
| Elucidation of thioredoxin as a molecular target for antitumor quinols TD Bradshaw, CS Matthews, J Cookson, EH Chew, M Shah, K Bailey, ... Cancer research 65 (9), 3911-3919, 2005 | 115 | 2005 |
| Peptide inhibitors of the Keap1–Nrf2 protein–protein interaction with improved binding and cellular activity R Hancock, M Schaap, H Pfister, G Wells Organic & biomolecular chemistry 11 (21), 3553-3557, 2013 | 108 | 2013 |
| Inhibition of DNA binding of the NF-Y transcription factor by the pyrrolobenzodiazepine-polyamide conjugate GWL-78 M Kotecha, J Kluza, G Wells, CC O'Hare, C Forni, R Mantovani, ... Molecular cancer therapeutics 7 (5), 1319-1328, 2008 | 89 | 2008 |
| Peptide and small molecule inhibitors of the Keap1–Nrf2 protein–protein interaction G Wells Biochemical Society Transactions 43 (4), 674-679, 2015 | 87 | 2015 |
| Structural studies on bioactive compounds. 32. Oxidation of tyrphostin protein tyrosine kinase inhibitors with hypervalent iodine reagents G Wells, A Seaton, MFG Stevens Journal of medicinal chemistry 43 (8), 1550-1562, 2000 | 87 | 2000 |
| Alkyl 4-[4-(5-oxo-2, 3, 5, 11a-tetrahydo-5H-pyrrolo [2, 1-c][1, 4] benzodiazepine-8-yloxy)-butyrylamino]-1H-pyrrole-2-carboxylate derivatives and related compounds for the … PW Howard, DE Thurston, G Wells US Patent 8,637,664, 2014 | 85 | 2014 |
| Quinols as novel therapeutic agents. 2. 4-(1-Arylsulfonylindol-2-yl)-4-hydroxycyclohexa-2, 5-dien-1-ones and related agents as potent and selective antitumor agents JM Berry, TD Bradshaw, I Fichtner, R Ren, CH Schwalbe, G Wells, ... Journal of medicinal chemistry 48 (2), 639-644, 2005 | 80 | 2005 |